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Abstract
The digital revolution is disrupting the ways in which health research is conducted, and subsequently, changing
healthcare. Direct-to-consumer wellness products and mobile apps, pervasive sensor technologies and access to
social network data offer exciting opportunities for researchers to passively observe and/or track patients ‘in the
wild’ and 24/7. The volume of granular personal health data gathered using these technologies is unprecedented,
and is increasingly leveraged to inform personalized health promotion and disease treatment interventions. The
use of artificial intelligence in the health sector is also increasing. Although rich with potential, the digital health
ecosystem presents new ethical challenges for those making decisions about the selection, testing, implementation
and evaluation of technologies for use in healthcare. As the ‘Wild West’ of digital health research unfolds, it is
important to recognize who is involved, and identify how each party can and should take responsibility to advance
the ethical practices of this work. While not a comprehensive review, we describe the landscape, identify gaps to
be addressed, and offer recommendations as to how stakeholders can and should take responsibility to advance
socially responsible digital health research.
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Background
The digital revolution is disrupting the ways in which
health research is conducted, and subsequently, chan-
ging healthcare [1–3]. The rise of digital health tech-
nologies has resulted in vast quantities of both
qualitative and quantitative ‘big data’, which contain
valuable information about user interactions and trans-
actions that may potentially benefit patients and care-
givers [4]. Digital data ‘exhaust’, or the traces of everyday
behaviors captured in our digital experiences, are of par-
ticular interest because they contain our natural behav-
iors gathered in real time. No doubt, important societal
conversations are needed to shape how these sociotech-
nical systems influence our lives as individuals, as well
as the impact on society [5]. While not a formal review,
this opinion essay provides a selective overview of the
rapidly changing digital health research landscape, iden-
tifies gaps, highlights several efforts that are underway to
address these gaps, and concludes with recommenda-
tions as to how stakeholders can and should take re-
sponsibility to advance socially responsible digital health
research.
Direct-to-consumer wellness products and mobile
apps (e.g., Fitbit, Strava), wearable research tools (e.g.,
SenseCam, ActivPAL), and access to social network data
offer exciting opportunities for individuals [6], as well as
traditional health researchers [7], to passively observe
and/or track individual behavior ‘in the wild’ and 24/7.
The volume of granular personal health data gathered
using these technologies is unprecedented, and is in-
creasingly leveraged to inform personalized health pro-
motion and disease treatment interventions. The use of
artificial intelligence (AI) tools in the health sector is
also increasing. For example, electronic health records
provide training data for machine learning that inform
algorithms, which can detect anomalies more accurately
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than trained humans – particularly in the fields of can-
cer, cardiology, and retinopathy [8]. The digital thera-
peutics sector is also seeking to expand and bring
products into the healthcare system, with the goal of
complementing or providing an alternative to traditional
medical treatments [9]. While the digital health revolu-
tion brings transformational promise for improving
healthcare, we must acknowledge our collective respon-
sibility to recognize and prevent unintended conse-
quences introduced by biased and opaque algorithms
that could exacerbate health disparities and jeopardize
public trust [10, 11]. Moreover, it is critical that the min-
imal requirements used to make a digital health technol-
ogy available to the public are not mistaken for a
product that has passed rigorous testing or demon-
strated real world therapeutic value [12].
Although rich with potential, the digital health ecosys-
tem presents new ethical challenges for those making
decisions about the selection, testing, implementation
and evaluation of technologies in healthcare. Researchers
began to study related ethical issues over 20 years ago,
when electronic health records technology was being
conceptualized [13], and as new forms of pervasive in-
formation communication technologies produce data,
guiding principles and standards are emerging within
academic research centers [14–16] and industry sectors
[17, 18]. Accepted ethical principles in health research,
including respect for persons, beneficence and justice,
remain relevant and must be prioritized to ensure that
research participants are protected from harms. Apply-
ing these principles in practice means that: people will
have the information they need to make an informed
choice; risks of harm will be evaluated against potential
benefits and managed; and no one group of people will
bear the burden of testing new health information tech-
nologies [19]. However, ethical challenges arise from the
combination of new, rapidly evolving technologies; new
stakeholders (e.g. technology giants, digital therapeutic
start-ups, citizen scientists); data quantity; novel compu-
tational and analytic techniques; and a lack of regulatory
controls or common standards to guide this convergence
in the health ecosystem.
It is of particular importance that these technologies
are finding their way into both research and clinical
practice without appropriate vetting. For example, we
have heard that, “if the product is free, then you’re the
product.” This means that our search terms, swipes,
clicks and keyboard interactions produce the data that
companies use to inform product improvement. These
‘big data’ are used to train algorithms to produce, for ex-
ample, tailored advertisements. Consumers allow this by
clicking “I Accept” to confirm their agreement with the
Terms and Conditions (T&C), which are not necessarily
intended to be easy to read or understand. Why does
this matter? When an algorithm is used to serve up a re-
minder about that yellow jacket you were eyeing, or the
summer vacation you mentioned to a friend the other
day, it may seem ‘creepy’, but it might be nice in terms of
convenience. Sometimes the AI gets it right, and other
times it is not even close. For example, if you were to
write something on Facebook that its proprietary AI in-
terprets as putting you at serious risk, it may send the
police to your home! Is Facebook getting it right? We do
not know: Facebook has claimed that, even though its al-
gorithm is not perfect and makes mistakes, it does not
consider its actions to be ‘research’ [20]. Aside from
threats to one’s privacy, we should question the process
of informed consent, whether there is an objective calcu-
lation of risk of harms against potential benefits, and
whether people included in the product testing phase
are those most likely to benefit.
Governance in the ‘wild west’
Those involved in the development, testing and deploy-
ment of technologies used in the digital health research
sector include technology developers or ‘tool makers’,
funders, researchers, research participants and journal
editors. As the ‘Wild West’ of digital health research
moves forward, it is important to recognize who is in-
volved, and to identify how each party can and should
take responsibility to advance the ethical practices of this
work.
Who is involved?
In the twentieth century, research was carried out by sci-
entists and engineers affiliated with academic institu-
tions in tightly controlled environments. Today,
biomedical and behavioral research is still carried out by
trained academic researchers; however, they are now
joined by technology giants, startup companies, non-
profit organizations, and everyday citizens (e.g. do-it-
yourself, quantified self ). The biomedical research sector
is now very different, but the lines are also blurred be-
cause the kind of product research carried out by the
technology industry has, historically, not had to follow
the same rules to protect research participants. As a re-
sult, there is potential for elevated risks of harm. More-
over, how and whether research is carried out to assess a
product’s effectiveness is variable in terms of standards
and methods, and, when the technology has health im-
plications, standards become critically important. In
addition, not all persons who initiate research are
regulated or professionally trained to design studies.
Specific to regulations, academic research environments
require the involvement of an ethics board (known as an
institutional review board [IRB] in the USA, and a re-
search ethics committee [REC] in the UK and European
Union). The IRB review is a federal mandate for entities
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that receive US federal funding to conduct health re-
search. The ethics review is a peer review process to
evaluate proposed research, and identify and reduce po-
tential risks that research participants may experience.
Having an objective peer review process is not a require-
ment for technology giants, startup companies or by
those who identify with the citizen science community
[10, 21]; however, we have a societal responsibility to get
this right.
What questions should be asked?
When using digital health technologies, a first step is to
ask whether the tools, be they apps or sensors or AI ap-
plied to large data sets, have demonstrated value with re-
spect to outcomes. Are they clinically effective? Do they
measure what they purport to measure (validity) consist-
ently (reliability)? For example, a recent review of the
predictive validity of models for suicide attempts and
death found that most are currently less than 1%; a
number at which they are not yet deemed to be clinical
viable [22]. Will these innovations also improve access
to those at highest risk of health disparities? To answer
these questions, it is critical that all involved in the
digital health ecosystem do their part to ensure the tech-
nologies are designed and scientifically tested in keeping
with accepted ethical principles; be considerate of priv-
acy, effectiveness, accessibility, utility; and have sound
data management practices. However, government agen-
cies, professional associations, technology developers,
academic researchers, technology startups, public orga-
nizations and municipalities may be unaware of what
questions to ask, including how to evaluate new tech-
nologies. In addition, not all tools being used in the
digital health ecosystem undergo rigorous testing, which
places the public at risk of being exposed to untested
and potentially flawed technologies.
Demonstrating value must be a precursor to the use of
any technologies that claim to improve clinical treat-
ment or population health. Value is based on the prod-
uct being valid and reliable, which means that scientific
research is needed before a product is deployed within
the health sector [12]. We should also not move ahead
assuming that privacy and the technology revolution are
mutually exclusive. We are in a precarious position in
which, without standards to shape acceptable and ethical
practices, we collectively run the risk of harming those
who stand to benefit most from digital health tools.
Decision-making framework
While there are discussions about the need for regula-
tions and laws, and incremental progress being made on
that front, until some consensus is reached, it is essential
that stakeholders recognize their obligation to promote
the integrity of digital health research [23]. The digital
health decision-making domains framework (Fig. 1) was
developed to help researchers make sound decisions
when selecting digital technologies for use in health re-
search [24, 25]. While originally developed for re-
searchers, this framework is applicable to various
stakeholders who might evaluate and select digital tech-
nologies for use in health research and healthcare. The
framework comprises five domains: 1, Participant Priv-
acy; 2 Risks and Benefits; 3, Access and Usability; 4, Data
Management; and 5, Ethical Principles. These five do-
mains are presented as intersecting relationships.
The domains in this framework were developed into a
checklist tool to further facilitate decision-making. The
checklist was informed via developmental research in-
volving a focus group discussion, and a design exercise
with behavioral scientists [25]. To demonstrate how the
decision-making domains can be put into practice, we
present a use case to illustrate the complexities and nu-
ances that are important for stakeholders to consider.
Use case: MoodFlex for mental health
MoodFlex is a private startup technology company that
has developed a mobile app to detect signals of poor
mental health by analyzing a person’s typing and voice
patterns from their smartphones. MoodFlex is negotiat-
ing with several municipalities to integrate their product
within the public mental healthcare system, with the
goal of delivering better services to people with mental
illness through predictive analytics. Since MoodFlex does
not claim to provide a clinical diagnosis or treatment,
approval from the US Food and Drug Administration is
not necessary. The vendor claims to have a proven prod-
uct; however, there are no publications documenting evi-
dence that it is safe, valid or reliable. The only research
that is formally acknowledged involves an evaluation of
the implementation process and uptake of the product
by health providers within the state mental health sys-
tem. The patient will be invited to download the app
after reviewing the vendor’s T&C – no other consent
process is proposed. The algorithm is proprietary, and
therefore, an external body is unable to determine
whether the algorithm that resulted from a machine-
learning process was trained on representative data, or
how decision-making occurs. Data captured about
people using the app are owned by the vendor.
Brief analysis
Before introducing MoodFlex into the public healthcare
system, decision makers – particularly the funding
organization – should evaluate evidence supporting the
efficacy of this product. Reproducible evidence is the
hallmark of evidence-based practice, and is the first step
prior to dissemination and implementation. If a product
is supported by evidence, the logical next step is the
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translational phase, in which a ‘dissemination and imple-
mentation’ (D&I) design is appropriate. Unfortunately,
many health apps move straight into a D&I phase before
the evidence exists to support that direction.
Lacking evidence that the product is effective,
decision-makers should recognize that a testing phase is
necessary. As with regulated research involving people, a
research plan should be developed and reviewed by an
external and objective ethics board (i.e., REC or IRB)
that will assess the degree to which people who are in-
vited do not bear an inappropriate burden (justice), po-
tential risks are offset by the benefits (beneficence), and
individuals are provided with an ability to make an in-
formed choice to volunteer (respect). At this early stage,
it is reasonable for the vendor to provide the sponsor
with a robust data management plan, with explicit lan-
guage regarding data ownership, access, sharing and
monitoring. When involving vulnerable populations,
such as those with a mental health diagnosis, additional
precautions should be considered to ensure that those
involved in the study are protected from harms – in-
cluding stigma, economic and legal implications. In
addition, it is important to consider whether some
people will be excluded because of access barriers. For
example, it may be necessary to adapt the technology to
be useful to non-English speakers. Informed consent
must also be obtained in a way that results in a person
making a choice to participate based on having adequate
and accessible information – this demonstrates the
principle of ‘respect for persons’, and is a hallmark of re-
search ethics. Placing consent language for a research
study in the T&C is unacceptable. For patients who be-
come research participants, it is particularly important
for them to understand the extent to which the
technology will support their healthcare needs. Patients
might falsely rely on the technology to provide the care
they believe they need when, in reality, they may need to
see their healthcare provider.
Digital research gaps and opportunities
This use case reflects the shift in health research associ-
ated with digital technologies, in that traditional
methods of developing an evidence base may be pushed
aside in favor of what appears to be exciting innovation.
The landscape is unsettled and potentially dangerous,
which makes governance important. We have identified
three notable gaps: 1, disciplinary/sector challenges; 2,
issues of data and technology literacy; and 3, inconsist-
ent or non-extant standards to guide the use of AI and
other emerging technologies in the healthcare settings.
Inter/trans/cross-disciplinary and sector challenges
Emerging technologies and AI systems require diverse
expertise when applied to digital medicine, which intro-
duces new challenges. Technology makers may not
understand patients’ needs, and develop tools with lim-
ited utility in practice [25, 26]. Computational scientists
may train AI using datasets that are not representative
of the public, limiting the ability to provide meaningful
assessments or predictions [27]. Clinicians may not
know how to manage the depth of granular data, nor be
confident in decisions produced by AI [28]. Research is
needed to examine this disconnect, and identify strat-
egies to reduce gaps and improve meaningful connec-
tions between these groups that are integral to digital
health research and the use of AI in the health care
sector.
Fig. 1 Digital health decision-making framework and excerpts from the companion checklist designed to support researchers [24]
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Digital/tech-literacy
The idea that keystrokes and voice patterns can be used
to aid diagnosis of Parkinson’s disease remains impres-
sive, but now it may also be possible to use keystroke
dynamics, kinematics and voice patterns to detect men-
tal health problems [29]. Knowing this information may
create public concern if not communicated in a way that
is useful and contextual, adding to fear, skepticism and
mistrust. The ‘public’ includes policy-makers, educators,
regulators, science communicators, and those in our
healthcare system, including clinicians, patients, and
caregivers. Research is needed to increase our under-
standing of what these stakeholders know, what they
want to know, and how best to increase their technology
literacy. This information can then be used to inform
educational resources targeting specific stakeholders. For
example, when reviewing manuscripts reporting digital
health research, reviewers and editors should be aware
of how to evaluate new methodologies and computa-
tional analytics to verify the accuracy and appropriate-
ness of the research and results.
Ethical and regulatory standards
As new digital tools and AI-enabled technologies are de-
veloped for the healthcare market, they will need to be
tested with people. As with any research involving hu-
man participants, the ethics review process is critical.
Yet, our regulatory bodies (e.g., IRB) may not have the
experience or knowledge needed to conduct a risk as-
sessment to evaluate the probability or magnitude of po-
tential harms [30]. Technologists and data scientists who
are making the tools and training the algorithms may
not have received ethics education as part of their formal
training, which may lead to a lack of awareness regard-
ing privacy concerns, risks assessment, usability, and so-
cietal impact. They may also not be familiar with
regulatory requirements to protect research participants
[23]. Similarly, the training data used to inform the algo-
rithm development are often not considered to qualify
as human subjects research, which – even in a regulated
environment – makes a prospective review for safety po-
tentially unavailable.
New initiatives – what resources are available for
the digital health/medicine community?
Several initiatives have begun to address the ethical, legal
and social implications (ELSI) of the digital revolution in
healthcare. Prominent examples of such initiatives con-
cern AI. Specific to AI, the foci are broad, and include
autonomous vehicles, facial recognition, city planning,
the future of work, and in some cases, health. A few se-
lected examples of current AI efforts appear to be well-
funded and collaborative programs (see Table 1).
Across these initiatives are efforts to assess the poten-
tial ELSI of AI. Similar to the impact of the European
Union (EU)‘s General Data Protection Regulation
(GDPR) in countries beyond the EU, the intention of
groups assessing AI through an ELSI lens is to develop
standards that can be applied or adapted globally. In
practice, however, most current efforts to integrate ELSI
to AI are quite broad, and as a result, may overlap in
scope and lack specificity.
While AI has a place in the digital health revolutions,
the scope of technologies goes well beyond AI. Other
Table 1 AI initiatives underway to inform broad cross-sector standards
Program Goal Collaborators
The Partnership on AI [30] Develop/test and share best practices 80+ partners in 13 countries
AI-100 [31] Impact of AI on urban life by 2030 in
North America
E. Horvitz, R. Altman
Ethics and Governance of AI Fund [32] Conduct evidence-based research Berkman Klein Center, Harvard and MIT
Media Lab
AI Now Institute [33] Conduct evidence-based research New York University
Initiative on Ethics of Autonomous and
Intelligent Systems [34]
Develop standards, certifications, codes IEEE and ACM
Human Rights, Big Data and Technology
Project [35]
Analyze the use of big data, artificial
intelligence, associated technologies
University of Essex, United Nations
The Institute for Ethics in Artificial
Intelligence [36]
Explore fundamental issues affecting
the use and impact of AI
Technical University of Munich partnership
with Facebook
High-Level Expert Group on Artificial
Intelligence [37]
Recommend ELSI policy development
on AI
European Commission
Chinese Association for Artificial
Intelligence [38]
Unite artificial intelligence science and
technology professionals
Ministry of Civil Affairs, China
AI for Humanity [39] Create an international group of AI
experts to prepare for societal
transformation
Future of Life Institute, France
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initiatives are looking more specifically at ELSI in mobile
apps, social network platforms, and wearable sensors be-
ing used in digital research. These include, for example,
the Connected and Open Research Ethics (CORE) initia-
tive at the University of California (UC) San Diego Re-
search Center for Optimal Digital Ethics in Health
(ReCODE Health), the Pervasive Data Ethics for Compu-
tational Research (PERVADE) program at the University
of Maryland, and the Mobile Health ELSI (mHealthELSI)
project out of Sage Bionetworks and the University of
Louisville. What these initiatives have in common is a goal
to inform policy and governance in a largely unregulated
space. These initiatives are but a few examples, and it is
important to note that many laboratories and institutes
are working on digital health ELSI.
Conclusion
Being mindful of new health technologies with new ac-
tors in the arena, the gap between known and unknown
risks fundamentally challenges the degree to which
decision-makers can properly evaluate the probability
and magnitude of potential harms against benefits. Now
is the time to take a step back and develop the infra-
structure necessary for vetting new digital health tech-
nologies, including AI, before deploying them into our
healthcare system. Selecting and implementing technolo-
gies in the digital health ecosystem requires consider-
ation of ethical principles, risks and benefits, privacy,
access and usability, and data management. New tech-
nologies have the potential to add important value; how-
ever, without careful vetting, may exacerbate health
disparities among those most vulnerable.
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